BBIO News and Press, BridgeBio Pharma Inc. From 02/12/26

2026-02-12 15:04:10 ET Andrew Tsai from Jefferies issued a price target of $100.00 for BBIO on 2026-02-12 19:07:50. The adjusted price target was set to $100.00. At the time of the announcement, BBIO was trading at $76.06. The overall price target consensus is at $96.82 ...

2026-02-12 14:15:07 ET Jefferies analyst issues BUY recommendation for BBIO on February 12, 2026 07:07PM ET. The previous analyst recommendation was Buy. BBIO was trading at $77.67 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2026-02-12 09:20:23 ET Denver, Colorado- Markets are digesting a wave of corporate developments spanning biotech innovation, AI infrastructure, edge computing and digital asset tokenization, with several companies delivering headline-grabbing updates that could shape sector narratives in 20...

2026-02-12 08:19:29 ET More on BridgeBio Pharma BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Pre...

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified explo...

2026-02-09 01:10:13 ET Initiating BridgeBio with a neutral rating I initiate coverage of Bridge Bio ( BBIO ) with a neutral rating, which reflects the balance between tangible de-risking following the US approval/early commercialization of acoramidis (Attruby) in the transthyret...

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBI...

2026-01-16 05:03:45 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bri...

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the &#x...

2026-01-14 16:09:21 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bri...